Aeglea Bio Therapeutics Inc
Change company Symbol lookup
Select an option...
AGLE Aeglea Bio Therapeutics Inc
EVRG Evergy Inc
ULIHF United Laboratories International Holdings Ltd
ABOIF Aboitiz Equity Ventures Inc
VYNE Vyne Therapeutics Inc
CEAD CEA Industries Inc
BFRI Biofrontera Inc
ARW Arrow Electronics Inc
SF-B Stifel Financial Corp
GSHRF Goldshore Resources Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Aeglea BioTherapeutics, Inc. is a clinical-stage biotechnology company. It is focused on human enzyme therapeutics to treat people with rare metabolic diseases. Its lead product candidate is pegzilarginase, which is a recombinant human arginase 1 that enzymatically degrades the amino acid arginine to lower arginine levels in patients with Arginase 1 Deficiency. It has engineered pegzilarginase with modifications that enhance the stability and arginine-degrading activity of the enzyme in human plasma. Its second product candidate, AGLE-177, is a novel PEGylated ( polyethylene glycol) human enzyme engineered to degrade free homocysteine and homocystine in patients with Homocystinuria. The Company is evaluating Pegzilarginase in a global pivotal Phase III pivotal PEACE (Pegzilarginase Effect on Arginase one Deficiency Clinical Endpoints) trial and Phase I/II open-label extension trial. It is also conducting a Phase I/II clinical trial for the treatment of patients with Homocystinuria.

Price
Delayed
$0.4964
Day's Change
-0.0137 (-2.69%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.538
Day's Low
0.4933
Volume
(Light)

Today's volume of 110,328 shares is on pace to be much lighter than AGLE's 10-day average volume of 843,322 shares.

110,328

Display:

Providers:

UpdateCancel
6 providers
June 02, 2022
Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it received a Refusal to File (RTF)...(PR Newswire)

May 05, 2022
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market

Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solutions for rare metabolic diseases, today announced that it has entered into a securities...(PR Newswire)

Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates

Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional PEACE data supporting potential efficacy of pegzilarginase presented at SIMD (PR Newswire)

April 12, 2022
Thinking about buying stock in Actinium Pharmaceuticals, BioCardia, Veru, Biodesix, or Aeglea Bio Therapeutics?

InvestorsObserver issues critical PriceWatch Alerts for ATNM, BCDA, VERU, BDSX, and AGLE. https://mma.prnewswire.com/media/1333368/InvestorsObserver_Logo.jpg To see how InvestorsObserver's proprietary scoring system rates these stocks, view the...(PR Newswire)

Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency

BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on next steps in the review process If approved, pegzilarginase would be the first FDA-approved...(PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.